Skip to Content
MilliporeSigma
  • Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.

Foscarnet salvage therapy for acyclovir-resistant varicella zoster: report of a novel thymidine kinase mutation and review of the literature.

The Pediatric infectious disease journal (2007-12-29)
Todd Hatchette, Graham A Tipples, Geoff Peters, Ahmed Alsuwaidi, Jianwei Zhou, Timothy Lloyd Mailman
ABSTRACT

The authors describe an acyclovir-resistant varicella zoster virus infection in a pediatric patient after hematopoietic stem cell transplant, the use of foscarnet as salvage therapy, and review the literature to clarify the pediatric experience with foscarnet in this setting. A novel thymidine kinase mutation is described, along with a new phenotypic assay for characterizing acyclovir resistance in varicella zoster virus.

MATERIALS
Product Number
Brand
Product Description

Aciclovir, European Pharmacopoeia (EP) Reference Standard
USP
Acyclovir, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Acycloguanosine, ≥99% (HPLC), powder
Supelco
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material